[1] 林勇,曾欣,胡平方.中国肝硬化临床诊治共识意见[J].临床肝胆病杂志,2023,39(9):2057-2073.
[2] Helil AS,Haile SA,Birhanu Y,et al.Bacterial profile,drug resistance pattern,clinical and laboratory predictors of ascites infection in cirrhosis patients[J].BMC Infect Dis,2024,24(1):528.
[3] Cannon MD,Martin P,Carrion AF.Bacterial infection in patients with cirrhosis:don't get bugged to death[J].Dig Dis Sci,2020,65(1):31-37.
[4] Martin Mateos R,Albillos A.Sepsis in patients with cirrhosis awaiting liver transplantation:new trends and management[J].Liver Transpl,2019,25(11):1700-1709.
[5] Lan NN,Lieu DQ,Anh TN,et al.Characteristics and related factors of bacterial infection among patients with cirrhosis[J].Mater Sociomed,2024,36(1):90-96.
[6] Dirchwolf M,Gomez Perdiguero G,Grech IM,et al.Challenges and recommendations when selecting empirical antibiotics in patients with cirrhosis[J].World Hepatol,2023,15(3):377-385.
[7] Zhang YY,Luo S,Li H,et al.Characterization of acute-on-chronic liver diseases:a multicenter prospective cohort study[J].World Hepatol,2024,16(5):809-821.
[8] Lazzarotto C,Ronsoni M,Fayad L,et al.Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis[J].Ann Hepatol,2013,12(4):599-607.
[9] 韩艳华,黄光强,蔡美玲,等.血清淀粉样蛋白A的检测方法及临床应用研究进展[J].生物化工,2024,10(3):211-215.
[10] 张素梅,景富春,姜晓倩,等.血清PCT、SAA及IL-6联合检测对肝硬化腹水合并腹腔感染的诊断和预后评估价值[J].临床误诊误治,2021,34(12):45-48,63.
[11] 武志芳,张刚强,韩春滔.血清PCT、IL-6在细菌感染患儿中的诊断价值[J].生物医学工程学进展,2024,45(3):228-233.
[12] 李欣,孙巨军,段婵荣,等.血清PCT、CRP和IL-6联合检测对肝硬化合并腹水感染的诊断价值[J].临床医学研究与实践,2022,7(9):116-119.
[13] Salguero S,Medrano LM,Gonzalez-Garcia J,et al.Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis:a cross-sectional study[J].Sci Rep,2020,10(1):10384.
[14] Mohamed AA,Abdelhamid M,El-Toukhy N,et al.Predictive and prognostic value of ascitic fluid mannose binding lectin in patients with spontaneous bacterial peritonitis[J].Antiinflamm Antiallergy Agents Med Chem,2021,20(2):196-200.
[15] Josifovikj FL,Stardelova KG,Todorovska B,et al.Diagnostic potential of calprotectin for spontaneous bacterial peritonitis in patients withliver cirrhosis and ascites[J].Pril (Makedon Akad Nauk Umet Odd Med Nauki),2021,42(3):97-106.
[16] Barreto CMA,do Valle EA,Moreira JPL,et al.Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis[J].Ann Hepatol,2024,30(1):101567.
[17] Wu PS,Hsieh YC,Lee KC,et al.Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients[J].PLoS One,2021,16(10):258589.
[18] Dibos M,Mayr U,Triebelhorn J,et al.Infections and liver cirrhosis[J].Med Klin Intensivmed Notfmed,2024,119(6):465-469.
[19] Shi P,Liu J,Liang A,et al.Application of metagenomic next-generation sequencing in optimizing the diagnosis of ascitic infection in patients with liver cirrhosis[J].BMC Infect Dis,2024,24(1):503.
[20] Li B,Hong C,Fan Z,et al.Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosis[J].Hepatol,2023,78(2):322-332.
[21] Wang ZK,Yang YS,Stefka AT,et al.Review article:fungal microbiota and digestive diseases[J].Aliment Pharmacol Ther,2014,39(8):751-766.
[22] Tu B,Zhang YN,Bi JF,et al.Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis[J].World Gastroenterol,2020,26(29):4316-4326. |
2025, Vol. 31 
